Understand any stock in simple English
Enter a ticker to learn what the company does and how it makes money.
Amgen makes and sells biologic medicines for serious diseases like cancer, kidney disease, and high cholesterol.
Amgen is a drugmaker, but not the kind that stuffs pills into bottles. It builds complex medicines out of living cells, called biologics, and sells them to hospitals, clinics, and patients — mostly in the United States. Its big products treat kidney disease, help cancer patients fight infections, and lower cholesterol. It also sells a drug that helps regrow bone marrow after chemotherapy and runs a growing business making "biosimilars," which are cheaper copies of other companies' biologic drugs once their patents expire.
The money flows in through insurance companies, government programs like Medicare, and hospitals, which pay for these drugs — often thousands of dollars per treatment. Customers pick Amgen because switching biologics is hard and risky; once a patient is on a drug that works, doctors are reluctant to change it. That stickiness is a moat. But it's an expensive business: developing a new drug takes years and billions of dollars, and most experiments fail. Amgen spends roughly a fifth of its revenue on research and development, a huge bet each year on molecules that mostly won't work. The company is based in Thousand Oaks, California, and it's one of the oldest and biggest independent biotech firms, founded in 1980. Its crown jewels have been two blockbuster drugs: Enbrel, for arthritis and other inflammatory diseases, and Neulasta, which boosts white blood cells in cancer patients. Both have faced cheaper competition. The grandest of its recent bets is Repatha, a cholesterol drug that cuts the risk of heart attacks but costs thousands a year — insurers fight over who pays for it. Amgen has also pushed into weight-loss drugs, because the obesity market turned into one of medicine's biggest gold rushes, though it is behind leaders Eli Lilly and Novo Nordisk.
Amgen makes plenty of cash and has spent heavily buying other companies to refill its pipeline as older drugs lose protection and face copycats. Its biggest recent deal was the purchase of Horizon Therapeutics, which brought rare-disease drugs — and regulatory scrutiny — along with it. It also buys back shares and pays a dividend. The honest risk: few companies are as dependent on a handful of aging products, and the price pressures from insurers and government programs keep squeezing what it can charge.
Saved answer · last researched 24 Oct 2026